ArticleInternational urology and nephrology2020
Resistin hormone in diabetic kidney disease and its relation to iron status and hepcidin.
Article in International urology and nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 9 citations in OpenAlex.
- The Influence of Body Composition, Lifestyle, and Dietary Components on Adiponectin and Resistin Levels and AR Index in Obese Individuals.International journal of molecular sciences · 2025Article
- Adipose knockout of H-ferritin improves energy metabolism in mice.Molecular metabolism · 2024Article
- Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease.Nature reviews. Nephrology · 2023Review
- In-depth review: is hepcidin a marker for the heart and the kidney?Molecular and cellular biochemistry · 2021Review
- Novel Iron Parameters in Patients with Type 2 Diabetes Mellitus in Relation to Kidney Function.Journal of clinical medicine · 2021Article
- Pentraxin-3 and adropin as inflammatory markers of early renal damage in type 2 diabetes patients.International urology and nephrology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundResistin, a potent adipocyte-secreted hormone, may contribute to and modulate iron status and hepcidin level in patients with non-insulin-dependent diabetes mellitus (NIDDM) and end-stage renal disease (ESRD). CONTEXT: The cross-sectional study aimed to determine the possible role of resistin in the iron status pathway in patients with NIDDM and ESRD events are sparse with conflicting results.
methodsA total of 130 patients and 42 healthy subjects were included in the study and grouped into four none obese groups with normal C-reactive protein (CRP) level: Group 1 (control), Group 2 (NIDDM), Group 3 (ESRD on hemodialysis), and Group 4 (NIDDM + ESRD on hemodialysis). Resistin hormone, ferritin, hepcidin, serum iron, TIBC, and TS% were estimated.
resultsResistin, hepcidin, and ferritin were significantly increased in all groups when compared to control. TIBC significantly increased in ESRD and NIDDM + ESRD when compared to controls. Serum iron and TS% significantly decreased in all groups when compared to controls. Resistin showed a significant positive correlation with hepcidin and ferritin.
conclusionIt was determined that serum resistin elevated in patients and correlated directly with hepcidin and ferritin levels. The present finding regarding receiver-operating characteristic curve (ROC curve) analysis of resistin hormone proposed that resistin could be represented as a biomarker for iron dysfunction in NIDDM and ESRD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.